Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReCOV Phase III COVID-19 Vaccine Trial in Adults
NCT05398848Phase 3Completed
- Sponsor
- Recbio
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing ReCOV with Placebo (2 arms). Primary endpoint: Efficacy of ReCOV in preventing RT-PCR confirmed symptomatic COVID-19. Started Oct 2022; status: completed.
02
Drugs
ReCOV
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05398848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398848.